Column Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Column Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$17.8K	Hold	91	–	–	﹤0.01%	446
2023 Q2	$19.1K	Hold	91	–	–	﹤0.01%	444
2023 Q1	$18.4K	Buy	91 +88	+2,933%	+$19.9K	﹤0.01%	456
2022 Q4	$654	Buy	+3	New	+$655	﹤0.01%	784
2020 Q3	–	Sell	-43	Closed	-$7K	–	720
2020 Q2	$7K	Buy	+43	New	+$6.86K	﹤0.01%	516

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Column Capital Advisors's CRL Position: Q3 2023 in Review

Column Capital Advisors held its Charles River Laboratories (CRL) position steady in Q3 2023 at 91 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #446.

Column Capital Advisors first reported a position in CRL in Q2 2020 and has held it in 5 quarters since. The position peaked at $19.1K in Q2 2023. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Column Capital Advisors held 91 shares of Charles River Laboratories worth $17.8K as of Q3 2023.
Column Capital Advisors left its Charles River Laboratories share count unchanged in Q3 2023.
Charles River Laboratories made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #446 holding.
Column Capital Advisors first reported a position in Charles River Laboratories in Q2 2020 and has held it in 5 quarters since.
Column Capital Advisors's Charles River Laboratories position peaked at $19.1K in Q2 2023.
621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.